Daidzein and the daidzein metabolite, equol, enhance adipocyte differentiation and PPARγ transcriptional activity

Journal of Nutritional Biochemistry

Volumn 21, Issue 9, 2010, Pages 841-847

  Cho, Kae Won ^a   Lee, Ok Hwan ^a   Banz, William J ^b   Moustaid Moussa, Naima ^c   Shay, Neil F ^d   Kim, Young Cheul ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY   (United States)

^c UNIVERSITY OF TENNESSEE   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

Adipocyte differentiation; Daidzein; Equol; GLUT4; Insulin sensitivity; PPAR

Indexed keywords

AP2 PROTEIN; CARRIER PROTEINS AND BINDING PROTEINS; DAIDZEIN; DEOXYGLUCOSE; EQUOL; GLUCOSE TRANSPORTER 4; INSULIN RECEPTOR SUBSTRATE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL STRAIN 3T3; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLUCOSE TRANSPORT; MOUSE; NONHUMAN; UPREGULATION;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; CELL DIFFERENTIATION; DEOXYGLUCOSE; FATTY ACID-BINDING PROTEINS; GLUCOSE; GLUCOSE TRANSPORTER TYPE 4; INSULIN RECEPTOR SUBSTRATE PROTEINS; ISOFLAVONES; MICE; PPAR GAMMA;

EID: 77955845051     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2009.06.012     Document Type: Article

References (48)

1. Olefsky J.M., Ciaraldi T.P., Kolterman O.G. Mechanisms of insulin resistance in non-insulin-dependent (type II) diabetes. Am J Med 1985, 79:12-22.
2. Olefsky J.M., Nolan J.J. Insulin resistance and non-insulin-dependent diabetes mellitus: cellular and molecular mechanisms. Am J Clin Nutr 1995, 61:980S-986S.
3. Lebovitz H.E. Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes 2001, 109:S135-S148.
4. Zimmet P., Alberti K.G., Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001, 414:782-787.
5. Mokdad A.H., Bowman B.A., Ford E.S., Vinicor F., Marks J.S., Koplan J.P. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001, 286:1195-1200.
6. Mokdad A.H., Ford E.S., Bowman B.A., Nelson D.E., Engelgau M.M., Vinicor F., et al. Diabetes trends in the U.S.: 1990-1998. Diabetes Care 2000, 23:1278-1283.
7. Ruan H., Lodish H.F. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev 2003, 14:447-455.
8. Melby M.K., Murashima M., Watanabe S. Phytochemical intake and relationship to past health history in Japanese women. Biofactors 2004, 22:265-269.
9. Hermansen K., Sondergaard M., Hoie L., Carstensen M., Brock B. Beneficial effects of a soy-based dietary supplement on lipid levels and cardiovascular risk markers in Type 2 diabetic subjects. Diabetes Care 2001, 24:228-233.
10. Anderson J.W., Johnstone B.M., Cook-Newell M.E. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 1995, 333:276-282.
11. Mezei O., Banz W.J., Steger R.W., Peluso M.R., Winters T.A., Shay N. Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells. J Nutr 2003, 133:1238-1243.
12. Davis J., Higginbotham A., O'Connor T., Moustaid-Moussa N., Tebbe A., Kim Y.C., et al. Soy protein and isoflavones influence adiposity and development of metabolic syndrome in the obese male ZDF rat. Ann Nutr Metab 2007, 51:42-52.
13. Jayagopal V., Albertazzi P., Kilpatrick E.S., Howarth E.M., Jennings P.E., Hepburn D.A., et al. Beneficial effects of soy phytoestrogen intake in postmenopausal women with type 2 diabetes. Diabetes Care 2002, 25:1709-1714.
14. Joffe B.I., Panz V.R., Raal F.J. From lipodystrophy syndromes to diabetes mellitus. Lancet 2001, 357:1379-1381.
15. Frayn K.N. Adipose tissue and the insulin resistance syndrome. Proc Nutr Soc 2001, 60:375-380.
16. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 2003, 14:137-145.
17. Abel E.D., Peroni O., Kim J.K., Kim Y.B., Boss O., Hadro E., et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 2001, 409:729-733.
18. Resh M.D. Development of insulin responsiveness of the glucose transporter and the (Na+,K+)-adenosine triphosphatase during in vitro adipocyte differentiation. J Biol Chem 1982, 257:6978-6986.
19. Cornelius P., MacDougald O.A., Lane M.D. Regulation of adipocyte development. Annu Rev Nutr 1994, 14:99-129.
20. Nadler S.T., Stoehr J.P., Schueler K.L., Tanimoto G., Yandell B.S., Attie A.D. The expression of adipogenic genes is decreased in obesity and diabetes mellitus. Proc Natl Acad Sci. U. S. A. 2000, 97:11371-11376.
21. Jansson P.A., Pellme F., Hammarstedt A., Sandqvist M., Brekke H., Caidahl K., et al. A novel cellular marker of insulin resistance and early atherosclerosis in humans is related to impaired fat cell differentiation and low adiponectin. FASEB J 2003, 17:1434-1440.
22. Rosen E.D., Spiegelman B.M. Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol 2000, 16:145-171.
23. Spiegelman B.M. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998, 47:507-514.
24. Rosen E.D., Hsu C.H., Wang X., Sakai S., Freeman M.W., Gonzalez F.J., et al. C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev 2002, 16:22-26.
25. Rosen E.D., Sarraf P., Troy A.E., Bradwin G., Moore K., Milstone D.S., et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999, 4:611-617.
26. Willson T.M., Cobb J.E., Cowan D.J., Wiethe R.W., Correa I.D., Prakash S.R., et al. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 1996, 39:665-668.
27. Berger J., Bailey P., Biswas C., Cullinan C.A., Doebber T.W., Hayes N.S., et al. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 1996, 137:4189-4195.
28. Chao L., Marcus-Samuels B., Mason M.M., Moitra J., Vinson C., Arioglu E., et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest 2000, 106:1221-1228.
29. Kim Y.C., Gomez F.E., Fox B.G., Ntambi J.M. Differential regulation of the stearoyl-CoA desaturase genes by thiazolidinediones in 3T3-L1 adipocytes. J Lipid Res 2000, 41:1310-1316.
30. Phillips M., Enan E., Liu P.C., Matsumura F. Inhibition of 3T3-L1 adipose differentiation by 2,3,7,8-tetrachlorodibenzo-p-dioxin. J Cell Sci 1995, 108:395-402.
31. Zhang J., Fu M., Cui T., Xiong C., Xu K., Zhong W., et al. Selective disruption of PPARgamma 2 impairs the development of adipose tissue and insulin sensitivity. Proc Natl Acad Sci. U. S. A. 2004, 101:10703-10708.
32. Le Lay S., Lefrere I., Trautwein C., Dugail I., Krief S. Insulin and sterol-regulatory element-binding protein-1c (SREBP-1C) regulation of gene expression in 3T3-L1 adipocytes. Identification of CCAAT/enhancer-binding protein beta as an SREBP-1C target. J Biol Chem 2002, 277:35625-35634.
33. Gomez F.E., Miyazaki M., Kim Y.C., Marwah P., Lardy H.A., Ntambi J.M., et al. Molecular differences caused by differentiation of 3T3-L1 preadipocytes in the presence of either dehydroepiandrosterone (DHEA) or 7-oxo-DHEA. Biochemistry 2002, 41:5473-5482.
34. Kliewer S.A., Forman B.M., Blumberg B., Ong E.S., Borgmeyer U., Mangelsdorf D.J., et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A 1994, 91:7355-7359.
35. Dang Z., Lowik C.W. The balance between concurrent activation of ERs and PPARs determines daidzein-induced osteogenesis and adipogenesis. J Bone Miner Res 2004, 19:853-861.
36. Clarkson T.B. Soy, soy phytoestrogens and cardiovascular disease. J Nutr 2002, 132:566S-569S.
37. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987, 262:5592-5595.
38. Setchell K.D. Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr 1998, 68:1333S-1346S.
39. Kelly G.E., Joannou G.E., Reeder A.Y., Nelson C., Waring M.A. The variable metabolic response to dietary isoflavones in humans. Proc Soc Exp Biol Med 1995, 208:40-43.
40. Setchell K.D., Clerici C., Lephart E.D., Cole S.J., Heenan C., Castellani D., et al. S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr 2005, 81:1072-1079.
41. Setchell K.D., Brown N.M., Desai P., Zimmer-Nechemias L., Wolfe B.E., Brashear W.T., et al. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr 2001, 131:1362S-1375S.
42. Setchell K.D., Brown N.M., Lydeking-Olsen E. The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr 2002, 132:3577-3584.
43. El-Jack A.K., Hamm J.K., Pilch P.F., Farmer S.R. Reconstitution of insulin-sensitive glucose transport in fibroblasts requires expression of both PPARgamma and C/EBPalpha. J Biol Chem 1999, 274:7946-7951.
44. Czech M.P. Molecular actions of insulin on glucose transport. Annu Rev Nutr 1995, 15:441-471.
45. Harmon A.W., Patel Y.M., Harp J.B. Genistein inhibits CCAAT/enhancer-binding protein beta (C/EBPbeta) activity and 3T3-L1 adipogenesis by increasing C/EBP homologous protein expression. Biochem J 2002, 367:203-208.
46. Zhang M., Ikeda K., Xu J.W., Yamori Y., Gao X.-M., Zhang B.-L. Genistein suppresses adipogenesis of 3T-L1 cells via multiple signal pathways. Phytother Res 2008, 10.1002/ptr.2724.
47. Watanabe S., Yamaguchi M., Sobue T., Takahashi T., Miura T., Arai Y., et al. Pharmacokinetics of soybean isoflavones in plasma, urine and feces of men after ingestion of 60 g baked soybean powder (kinako). J Nutr 1998, 128:1710-1715.
48. Izumi T., Piskula M.K., Osawa S., Obata A., Tobe K., Saito M., et al. Soy isoflavone aglycones are absorbed faster and in higher amounts than their glucosides in humans. J Nutr 2000, 130:1695-1699.